Maria Roche

2.5k total citations
64 papers, 1.3k citations indexed

About

Maria Roche is a scholar working on Reproductive Medicine, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Maria Roche has authored 64 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Reproductive Medicine, 17 papers in Pulmonary and Respiratory Medicine and 16 papers in Oncology. Recurrent topics in Maria Roche's work include Ovarian cancer diagnosis and treatment (27 papers), Intraperitoneal and Appendiceal Malignancies (12 papers) and Gastrointestinal Tumor Research and Treatment (9 papers). Maria Roche is often cited by papers focused on Ovarian cancer diagnosis and treatment (27 papers), Intraperitoneal and Appendiceal Malignancies (12 papers) and Gastrointestinal Tumor Research and Treatment (9 papers). Maria Roche collaborates with scholars based in United States, France and United Kingdom. Maria Roche's co-authors include Ursula A. Matulonis, Richard T. Penson, Carolyn Krasner, Michael V. Seiden, Susana M. Campos, Suzanne Berlin, Neil S. Horowitz, Stephen A. Cannistra, Hang Lee and Karin Tyburski and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Maria Roche

63 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Maria Roche United States	19	495	462	423	335	295	64	1.3k
C. Sessa Switzerland	13	267 0.5×	427 0.9×	651 1.5×	304 0.9×	63 0.2×	24	1.1k
Andrew Dean Australia	17	262 0.5×	272 0.6×	1.1k 2.6×	694 2.1×	169 0.6×	104	1.6k
Matthew Tan United States	7	208 0.4×	262 0.6×	558 1.3×	210 0.6×	155 0.5×	10	1.1k
Kaoru Niimi Japan	20	478 1.0×	371 0.8×	338 0.8×	524 1.6×	58 0.2×	101	1.7k
George Zarkavelis Greece	15	169 0.3×	130 0.3×	458 1.1×	170 0.5×	157 0.5×	52	813
Suzanne Berlin United States	15	333 0.7×	451 1.0×	408 1.0×	204 0.6×	223 0.8×	37	1.3k
Anderley Gordon United States	10	316 0.6×	923 2.0×	536 1.3×	139 0.4×	145 0.5×	32	1.3k
Shashikant Lele United States	16	425 0.9×	1.6k 3.5×	560 1.3×	319 1.0×	187 0.6×	29	2.5k
Isabel Bover Spain	13	401 0.8×	228 0.5×	1.3k 3.0×	1.3k 4.0×	108 0.4×	48	2.1k
Catherine Shannon Australia	20	148 0.3×	171 0.4×	704 1.7×	286 0.9×	183 0.6×	48	1.2k

Countries citing papers authored by Maria Roche

Since Specialization

Citations

This map shows the geographic impact of Maria Roche's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria Roche with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria Roche more than expected).

Fields of papers citing papers by Maria Roche

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maria Roche. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria Roche. The network helps show where Maria Roche may publish in the future.

Co-authorship network of co-authors of Maria Roche

This figure shows the co-authorship network connecting the top 25 collaborators of Maria Roche. A scholar is included among the top collaborators of Maria Roche based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maria Roche. Maria Roche is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yap, Timothy A., Manish R. Patel, Brian S. Henick, et al.. (2023). VELA: A first-in-human phase 1/2 study of BLU-222, a potent, selective cyclin-dependent kinase (CDK) 2 inhibitor in patients with cyclin E1 gene (CCNE1)-amplified or CDK4/6 inhibitor (CDK4/6i)-resistant advanced solid tumors (1275). Gynecologic Oncology. 176. S173–S173. 1 indexed citations

Jones, Robin L., César Serrano, Margaret von Mehren, et al.. (2021). Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial. European Journal of Cancer. 145. 132–142. 85 indexed citations

Jones, Robin L., Margaret von Mehren, Sally L. George, et al.. (2020). 115MO Long-term efficacy, tolerability and overall survival in patients (pts) with unresectable or metastatic (U/M) PDGFRA D842V-mutant gastrointestinal stromal tumour (GIST) treated with avapritinib: NAVIGATOR phase I trial update. Annals of Oncology. 31. S1287–S1288. 1 indexed citations

Jones, Robin L., César Serrano, Margaret von Mehren, et al.. (2020). 1621MO Long-term efficacy, tolerability and overall survival in patients (pts) with unresectable or metastatic (U/M) PDGFRA D842V-mutant gastrointestinal stromal tumour (GIST) treated with avapritinib: NAVIGATOR phase I trial update. Annals of Oncology. 31. S973–S973. 3 indexed citations

Krasner, Carolyn, Cesar M. Castro, Richard T. Penson, et al.. (2019). Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin. Gynecologic Oncology. 153(2). 223–229. 5 indexed citations

Daigle, Scott R., Silvia Stacchiotti, Patrick Schöffski, et al.. (2018). Molecular characterization of epithelioid sarcoma (ES) tumors derived from patients enrolled in a phase II study of tazemetostat (NCT02601950). Annals of Oncology. 29. viii670–viii670. 4 indexed citations

Chan-Penebre, Elayne, Kelli Armstrong, Allison E. Drew, et al.. (2017). Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models. Molecular Cancer Therapeutics. 16(5). 850–860. 127 indexed citations

Henrotin, Yves, et al.. (2017). Protective actions of microbiota intervention in two animal models of osteoarthritis: complementary approaches in spontaneous osteoarthritis in Dunkin Hartley Guinea pigs and surgically induced in rabbit. Osteoarthritis and Cartilage. 25. S413–S413. 1 indexed citations

Campos, Susana M., Richard T. Penson, Ursula A. Matulonis, et al.. (2012). A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma. Gynecologic Oncology. 128(2). 215–220. 41 indexed citations

10.

Roche, Maria, Carolyn Krasner, Ursula A. Matulonis, et al.. (2009). Phase II trial of GM-CSF in women with asymptomatic recurrent müllerian tumors. Gynecologic Oncology. 116(2). 168–172. 8 indexed citations

11.

Owen‐Smith, Ashli, et al.. (2008). Screening for Domestic Violence in an Oncology Clinic: Barriers and Potential Solutions. Oncology nursing forum. 35(4). 625–633. 18 indexed citations

12.

Matulonis, Ursula A., Suzanne Berlin, Carolyn Krasner, et al.. (2007). Phase II study of Cediranib (RECENTIN™, AZD2171) in recurrent epithelial ovarian cancer. Molecular Cancer Therapeutics. 6. 1 indexed citations

13.

Krasner, Carolyn, Michael V. Seiden, Arlan F. Fuller, et al.. (2007). Results of all-intraperitoneal carboplatin and paclitaxel regimen shows good tolerability and efficacy for advanced ovarian cancer. Journal of Clinical Oncology. 25(18_suppl). 5521–5521. 6 indexed citations

14.

Matulonis, Ursula A., Susana M. Campos, Carolyn Krasner, et al.. (2006). Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced müllerian malignancies: The modified triple doublet regimen. Gynecologic Oncology. 103(2). 575–580. 6 indexed citations

15.

Krasner, Carolyn, Maria Roche, Neil S. Horowitz, et al.. (2006). Case 11-2006. New England Journal of Medicine. 354(15). 1615–1625. 6 indexed citations

16.

Penson, Richard T., Michael V. Seiden, Ursula A. Matulonis, et al.. (2005). A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours. British Journal of Cancer. 93(1). 54–59. 5 indexed citations

17.

He, Xiaoying, et al.. (2005). Prolonged stabilization of platinum-resistant ovarian cancer in a single patient consuming a fermented soy therapy. Gynecologic Oncology. 100(1). 205–209. 16 indexed citations

18.

Seiden, Michael V., Franco M. Muggia, Ursula A. Matulonis, et al.. (2004). A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer. Gynecologic Oncology. 93(1). 229–232. 59 indexed citations

19.

Berkenblit, Anna, Michael V. Seiden, Ursula A. Matulonis, et al.. (2004). A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer. Gynecologic Oncology. 95(3). 624–631. 34 indexed citations

20.

Matulonis, Ursula A., Susana M. Campos, Linda Duska, et al.. (2003). A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies☆☆Funding provided by Eli Lilly Pharmaceutical Company and Amgen.. Gynecologic Oncology. 91(2). 293–298. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact